Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

September 30 2013

AIDS : News from the front | The Economist

AIDS: News from the front | The Economist

NO NEWS is often good news. AIDS has dropped out of the headlines in recent years, and that is because, in the battle between virus and people, people are winning.

This year’s campaign report by UNAIDS, the United Nations agency charged with combating the disease, confirms that optimistic picture. Though AIDS is not beaten (it still kills 1.6m people a year), this number is down from a peak of 2.3m in 2005. And the number of new infections per year has fallen by a third, to 2.3m, since 2001. Paradoxically, the number of those infected is rising. But this is because they are living longer.

#santé #sida

August 06 2013

Sida en Grèce : dépistages forcés et risque de prison pour les séropositifs - Le Courrier des…

#Sida en Grèce : dépistages forcés et risque de #prison pour les séropositifs - Le Courrier des Balkans

Le ministre grec de la Santé Adonis Georgiadis a réintroduit un décret sanitaire permettant à la police d’arrêter et de soumettre au test de dépistage du sida toute personne suspectée d’être un « danger potentiel de santé publique ». Prostituées, migrants et toxicomanes sont visés. Une législation qui pourrait permettre de justifier des actions portant atteinte aux droits de l’homme. Les organisations mondiales de la Santé se disent préoccupées.

July 03 2013

SIDA : la France se bat

#SIDA : la #France se bat

Ludovic Clerima

Plus de neuf Français séropositifs sur dix ont accès aux traitements antirétroviraux. Une bonne nouvelle, malgré la progression de la #maladie sur le continent européen.

C'est peut-être la bonne nouvelle de cette enquête. lire la (...)

#Société #INFO #Allemagne #Royaume-Uni #Russie #Ukraine #Union_européenne #Europe #OMS #séropositif #VIH #virus

July 02 2013

Untangling the Web of Antiretroviral Price Reductions (16th edition) | Médecins Sans Frontières…

Untangling the Web of Antiretroviral Price Reductions (16th edition) | Médecins Sans Frontières (MSF/ Doctors Without Borders)

Today at the International AIDS Society conference in Kuala Lumpur, Médecins Sans Frontières (MSF) launches two reports: the 16th edition of Untangling the Web of Antiretroviral Price Reductions, MSF's report on price and access issues around antiretrovirals (ARVs), medicines used to treat HIV; and Putting HIV Treatment to the Test: A Product Guide for Viral Load and Point-of-Care CD4 Diagnostic Tools

This year's edition of Untangling the Web finds that although the price of first- and second-line ARVs have come down thanks to increased generic competition, third-line or salvage regimens remain exorbitantly priced, with middle-income countries such as Armenia paying more than US$13,000 per person per year for raltegravir, just one of the three or four drugs needed in a third-line cocktail. MSF also finds that while patents remain a barrier on newer drugs and in middle-income countries, some countries are using World Trade Organization-sanctioned TRIPS flexibilities to issue compulsory licences to allow more affordable access. Voluntary licences, however, are the preferred method by originator companies of selling new, patented ARVs to countries, but those companies are increasingly excluding all but least-developed and sub-Saharan African countries from their licences. Free trade agreements are also increasingly posing a threat to access to medicines in negotiating countries, with the EU-India Free Trade Agreement and the Trans-Pacific Partnership Agreement causing the most concern over proposed harmful provisions.

MSF's pricing analysis also extends to viral load monitoring tests in Putting HIV Treatment to the Test. Routine evaluation of a person's viral load is important because it helps to identify who needs help in adhering to ART. Where adherence problems can be ruled out and treatment failure has already occurred (because drug resistance mutations have developed), viral load can help guide a switch to second-line treatment. Viral load can help prevent viral transmission, because non-viraemic patients (people with ‘undetectable' viral load) have a very low risk of transmitting HIV. Viral load is a much more accurate way than the commonly used CD4 count to determine how well someone is doing on treatment, potentially an avoiding unnecessary switch to more expensive second- or third-line treatment. However, current viral load tests are expensive and complex for remote and resource-limited settings. Putting HIV Treatment to the Test looks at these issues on a number of viral load and point of care CD4 diagnostic tests.

#brevets #santé #sida #génériques

Older posts are this way If this message doesn't go away, click anywhere on the page to continue loading posts.
Could not load more posts
Maybe Soup is currently being updated? I'll try again automatically in a few seconds...
Just a second, loading more posts...
You've reached the end.
Get rid of the ads (sfw)

Don't be the product, buy the product!